Skip to main content
Erschienen in: Journal of General Internal Medicine 10/2020

31.07.2020 | COVID-19 | Perspective Zur Zeit gratis

Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer

verfasst von: Monica Gandhi, MD, MPH, Chris Beyrer, MD, MPH, Eric Goosby, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Although the benefit of population-level public facial masking to protect others during the COVID-19 pandemic has received a great deal of attention, we discuss for one of the first times the hypothesis that universal masking reduces the “inoculum” or dose of the virus for the mask-wearer, leading to more mild and asymptomatic infection manifestations. Masks, depending on type, filter out the majority of viral particles, but not all. We first discuss the near-century-old literature around the viral inoculum and severity of disease (conceptualized as the LD50 or lethal dose of the virus). We include examples of rising rates of asymptomatic infection with population-level masking, including in closed settings (e.g., cruise ships) with and without universal masking. Asymptomatic infections may be harmful for spread but could actually be beneficial if they lead to higher rates of exposure. Exposing society to SARS-CoV-2 without the unacceptable consequences of severe illness with public masking could lead to greater community-level immunity and slower spread as we await a vaccine. This theory of viral inoculum and mild or asymptomatic disease with SARS-CoV-2 in light of population-level masking has received little attention so this is one of the first perspectives to discuss the evidence supporting this theory.
Literatur
4.
Zurück zum Zitat Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. N Engl J Med 2020; 382:2158-2160CrossRef Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. N Engl J Med 2020; 382:2158-2160CrossRef
5.
Zurück zum Zitat He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26(5): 672-5.CrossRef He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26(5): 672-5.CrossRef
7.
Zurück zum Zitat Lyu W, Wehby GL. Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US. Health Aff (Millwood) 2020: 101377hlthaff202000818. Accessed June 22, 2020 Lyu W, Wehby GL. Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US. Health Aff (Millwood) 2020: 101377hlthaff202000818. Accessed June 22, 2020
10.
Zurück zum Zitat Gandhi M, Havlir D. The Time for Universal Masking of the Public for Coronavirus Disease 2019 Is Now. Open Forum Infect Dis 2020; 7(4): ofaa131.CrossRef Gandhi M, Havlir D. The Time for Universal Masking of the Public for Coronavirus Disease 2019 Is Now. Open Forum Infect Dis 2020; 7(4): ofaa131.CrossRef
11.
Zurück zum Zitat Eikenberry SE, Mancuso M, Iboi E, et al. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. Infect Dis Model 2020; 5: 293-308.PubMedPubMedCentral Eikenberry SE, Mancuso M, Iboi E, et al. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. Infect Dis Model 2020; 5: 293-308.PubMedPubMedCentral
12.
Zurück zum Zitat Handel A, Li Y, McKay B, Pawelek KA, Zarnitsyna V, Antia R. Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design. PLoS Comput Biol 2018; 14(10): e1006505.CrossRef Handel A, Li Y, McKay B, Pawelek KA, Zarnitsyna V, Antia R. Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design. PLoS Comput Biol 2018; 14(10): e1006505.CrossRef
13.
Zurück zum Zitat Miller DS, Kok T, Li P. The virus inoculum volume influences outcome of influenza A infection in mice. Lab Anim 2013; 47(1): 74-7.CrossRef Miller DS, Kok T, Li P. The virus inoculum volume influences outcome of influenza A infection in mice. Lab Anim 2013; 47(1): 74-7.CrossRef
14.
Zurück zum Zitat Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress 2020; 4(4): 66-75.CrossRef Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress 2020; 4(4): 66-75.CrossRef
15.
Zurück zum Zitat Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China, JAMA Netw Open 2020; 3(5): e2010182.CrossRef Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China, JAMA Netw Open 2020; 3(5): e2010182.CrossRef
16.
Zurück zum Zitat Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis 2020. Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis 2020.
17.
Zurück zum Zitat McKenney DG, Kurath G, Wargo AR. Characterization of infectious dose and lethal dose of two strains of infectious hematopoietic necrosis virus (IHNV). Virus Res 2016; 214: 80-9.CrossRef McKenney DG, Kurath G, Wargo AR. Characterization of infectious dose and lethal dose of two strains of infectious hematopoietic necrosis virus (IHNV). Virus Res 2016; 214: 80-9.CrossRef
18.
Zurück zum Zitat Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. The American Journal of Hygiene. 1938;27(3):493-7. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. The American Journal of Hygiene. 1938;27(3):493-7.
19.
Zurück zum Zitat Casadevall A. The Pathogenic Potential of a Microbe. mSphere 2017; 2(1). Casadevall A. The Pathogenic Potential of a Microbe. mSphere 2017; 2(1).
20.
Zurück zum Zitat Bouvier NM, Lowen AC. Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses 2010; 2(8): 1530-63.CrossRef Bouvier NM, Lowen AC. Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses 2010; 2(8): 1530-63.CrossRef
21.
Zurück zum Zitat Tao X, Garron T, Agrawal AS, et al. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol 2016; 90(1): 57-67.CrossRef Tao X, Garron T, Agrawal AS, et al. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol 2016; 90(1): 57-67.CrossRef
22.
Zurück zum Zitat Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, et al. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. PLoS Genet. 2015;11(10):e1005504. .CrossRef Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, et al. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. PLoS Genet. 2015;11(10):e1005504. .CrossRef
23.
Zurück zum Zitat Roberts A, Deming D, Paddock CD, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 2007; 3(1): e5.CrossRef Roberts A, Deming D, Paddock CD, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 2007; 3(1): e5.CrossRef
24.
Zurück zum Zitat Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004; 78(7): 3572-7.CrossRef Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004; 78(7): 3572-7.CrossRef
25.
Zurück zum Zitat Virlogeux V, Fang VJ, Wu JT, et al. Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection. Epidemiology 2015; 26(5): 666-9.CrossRef Virlogeux V, Fang VJ, Wu JT, et al. Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection. Epidemiology 2015; 26(5): 666-9.CrossRef
28.
Zurück zum Zitat Smereka J, Ruetzler K, Szarpak L, Filipiak KJ, Jaguszewski M. Role of mask/respirator protection against SARS-CoV-2. Anesth Analg 2020. Accessed June 22, 2020 Smereka J, Ruetzler K, Szarpak L, Filipiak KJ, Jaguszewski M. Role of mask/respirator protection against SARS-CoV-2. Anesth Analg 2020. Accessed June 22, 2020
29.
Zurück zum Zitat Engelking HM, Leong JC. The glycoprotein of infectious hematopoietic necrosis virus elicits neutralizing antibody and protective responses. Virus Res 1989; 13(3): 213-30.CrossRef Engelking HM, Leong JC. The glycoprotein of infectious hematopoietic necrosis virus elicits neutralizing antibody and protective responses. Virus Res 1989; 13(3): 213-30.CrossRef
30.
Zurück zum Zitat S.E. LaPatra, J.L. Fryer, J.S. Rohovec. Virulence comparison of different electropherotypes of infectious hematopoietic necrosis virus. Dis. Aquat. Org., 16 (1993), pp. 115-1.CrossRef S.E. LaPatra, J.L. Fryer, J.S. Rohovec. Virulence comparison of different electropherotypes of infectious hematopoietic necrosis virus. Dis. Aquat. Org., 16 (1993), pp. 115-1.CrossRef
31.
Zurück zum Zitat Kim R, Faisal M. Comparative susceptibility of representative Great Lakes fish species to the North American viral hemorrhagic septicemia virus Sublineage IVb. Dis Aquat Organ 2010; 91(1): 23-34.CrossRef Kim R, Faisal M. Comparative susceptibility of representative Great Lakes fish species to the North American viral hemorrhagic septicemia virus Sublineage IVb. Dis Aquat Organ 2010; 91(1): 23-34.CrossRef
32.
Zurück zum Zitat Brown JD, Stallknecht DE, Berghaus RD, Swayne DE. Infectious and lethal doses of H5N1 highly pathogenic avian influenza virus for house sparrows (Passer domesticus) and rock pigeons (Columbia livia). J Vet Diagn Invest 2009; 21(4): 437-45.CrossRef Brown JD, Stallknecht DE, Berghaus RD, Swayne DE. Infectious and lethal doses of H5N1 highly pathogenic avian influenza virus for house sparrows (Passer domesticus) and rock pigeons (Columbia livia). J Vet Diagn Invest 2009; 21(4): 437-45.CrossRef
33.
Zurück zum Zitat S.E. LaPatra, J.L. Fryer, J.S. Rohovec. Virulence comparison of different electropherotypes of infectious hematopoietic necrosis virus. Dis. Aquat. Org., 16 (1993), pp. 115-120.CrossRef S.E. LaPatra, J.L. Fryer, J.S. Rohovec. Virulence comparison of different electropherotypes of infectious hematopoietic necrosis virus. Dis. Aquat. Org., 16 (1993), pp. 115-120.CrossRef
34.
Zurück zum Zitat Memoli MJ, Czajkowski L, Reed S, et al. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis 2015; 60(5): 693-702.CrossRef Memoli MJ, Czajkowski L, Reed S, et al. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis 2015; 60(5): 693-702.CrossRef
37.
Zurück zum Zitat Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020; 25(10). Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020; 25(10).
39.
Zurück zum Zitat Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. JAMA 2020;323(23):2424-2425CrossRef Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. JAMA 2020;323(23):2424-2425CrossRef
Metadaten
Titel
Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer
verfasst von
Monica Gandhi, MD, MPH
Chris Beyrer, MD, MPH
Eric Goosby, MD
Publikationsdatum
31.07.2020
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Journal of General Internal Medicine / Ausgabe 10/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-06067-8

Weitere Artikel der Ausgabe 10/2020

Journal of General Internal Medicine 10/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.